Dietary Intervention With Probiotic Pasta and Evaluation of the Effects on Metabolic and Inflammatory Status

Overweight and Obesity Clinical Trial

— ProPas  

Official title:

Dietary Intervention With Probiotic Pasta and Evaluation of the Effects on Metabolic and Inflammatory Status in Overweight and Obese Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04962633
• Other study ID #: ProPas
• Status: Completed
• Phase: N/A
• Start date: January 1, 2022
• Est. completion date: December 31, 2022

Study information

• Verified date: February 2023
• Source: Federico II University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to investigate the effects of daily consumption for 4 weeks of a probiotic durum wheat pasta vs a conventional durum wheat pasta without probiotics on fasting metabolic parameters and inflammatory status, on gut permeability and functionality, on daily energy intakes, appetite feelings, body weight, body mass index (BMI), waist and hip circumferences, blood pressure, body composition and wellbeing status in overweight and obese subjects.

Description:

Growing evidence highlights the role of the individual diet and gut microbiome in modulating human metabolism, inflammatory status and cardiovascular risk.

This scenario supports nutritional approaches targeted to modify gut microbiota composition to trigger health benefits and the interest to develop novel functional foods enriched with probiotics. Most of commercial probiotic foods are in the category of dairy products and contain Lactobacillus strains. Besides that, Bacillus spp. along with the ability to form spores show probiotic attributes by exhibiting pathogen exclusion and antioxidant, antimicrobial and immune-modulatory abilities. Furthermore, they possess a stronger viability and stability to withstand high temperature processes, such as baking and boiling, than other probiotic bacteria thus representing an ideal choice for the development of functional cereal-based products.

In particular, Bacillus clausii UBBC07 exhibits probiotic properties by alleviating the severity and symptoms of acute diarrhoea in adults and children and show a high stability over a wide range of temperatures with potential applications in a variety of formulations and foods. The health benefits of B. clausii UBBC07 in overweight and obese subjects is unexplored.

This study aims to investigate the effects of consumption for 4 weeks of a probiotic durum wheat pasta enriched with spores of B. clausii UBBC07 vs a conventional durum wheat pasta (control) on metabolic and inflammatory status, on gut permeability and functionality, on daily energy intakes, appetite feelings, body weight, body mass index (BMI), waist and hip circumferences, blood pressure, body composition and wellbeing status in overweight and obese subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 31, 2022
• Est. primary completion date: December 23, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• healthy subjects;

• men and women;

• age 18-65 years;

• 25 kg/m2 = BMI = 35 kg/m2;

• habitual daily pasta consumption (= 1 portion/day);

• habitual diet characterized by absence of any food supplements and alternative medication, probiotics and prebiotics, whole grain and/or fiber enriched foods;

• intake of fruit/vegetables < 3 servings/day;

• low level of physical activity (< 500 metabolic equivalent min/week);

• signed written informed consent.

Exclusion Criteria:

• food allergies and intolerances and celiac disease;

• gastrointestinal diseases;

• relevant diseases;

• pregnant or breastfeeding;

• previous abdominal surgery;

• hypertriglyceridemia (Triglycerides > 200 mg/dL);

• hypercholesterolemia (Total cholesterol > 200 mg/dL);

• hyperglycaemia (glycaemia = 110 mg/dL);

• hypertension (arterial blood pressure =140/90 mm Hg);

• weight loss = 3 kg within 2 months before the study;

• antibiotics treatment within 3 months before the study;

• any medication (different from antibiotics) at the enrollment and within 2 months before the study;

• habitual diet characterized by high fruit and vegetables intakes (>3 portion/die);

• high level of physical activity;

• Alcohol consumption = 3 alcohol units per day;

• simultaneous participation in other trial.

Related Conditions & MeSH terms

• Overweight
• Overweight and Obesity

Intervention

Other:
• Probiotic Pasta
Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
• Control Pasta
Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.

Locations

Country	Name	City	State
Italy	Department of Agricultural Sciences	Portici

Sponsors (1)

Lead Sponsor	Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in fasting inflammatory blood markers	Measure of plasma C-reactive protein (mmol/L)	1 months
Primary	Changes in fasting plasma lipids	Measure of plasma concentrations (mg/dL) of Total-, LDL-, and HDL-Cholesterol, as well as Triglycerides	1 months
Primary	Changes in fasting plasma glucose	Measure of plasma glucose concentrations (mg/dL)	1 months
Secondary	Changes in small intestine permeability	Measure of lactulose and mannitol excreted in urines collected in the 0-5 hours time interval after an oral challenge with 5 g lactulose, 2 g mannitol and 2 g sucralose dissolved in 100 mL of water. The amounts of lactulose and mannitol excreted will be expressed in milligrams, and their ratio (lactulose/mannitol) will be calculated and used as marker of small intestine permeability	1 month
Secondary	Changes in colonic permeability	Measure of sucralose excreted in urines collected over 24 hours after an oral challenge with 5 g lactulose, 2 g mannitol and 2 g sucralose dissolved in 100 mL of water. The amount of sucralose excreted will be expressed in milligrams and will be used as marker of colonic permeability	1 month
Secondary	Changes in stool consistency	Measure of consistency of feces by mean of King's stool chart filled out by subjects. The chart comprises four categories of stool consistency: hard and formed, soft and formed, loose and unformed, liquid.	1 month
Secondary	Changes in stool weight	Measure of stool weight by mean of King's stool chart filled out by subjects. The chart comprises three categories of stool weight : <100 g, 100-200 g, >200 g.	1 month
Secondary	Changes in stool frequency	Measure of frequency of feces by mean of King's stool chart filled out by subjects. Fecal frequency is incorporated by recording the code of each feces passed over a 24 hour period.	1 month
Secondary	Changes in gastrointestinal functionality	Calculation of daily fecal score from summation of all scores for stool consistency, weight and frequency obtained from King's stool chart filled out by subjects. Scores are weighted such that an increase in fecal frequency alone results in a higher score than a change in fecal consistency alone, which in turn results in a higher score than an increase in fecal weight alone. Diarrhea is classified by a daily fecal score of 15 or more.	1 month
Secondary	Changes in faecal microbiome	The composition of faecal microbiome will be determined by high throughput sequencing of the 16S ribosomal ribonucleic acid (rRNA) gene. The massive number of sequences obtained will be analyzed by using state of the art bioinformatics tools and the presence and relative abundance of the microbial species occurring in each sample will be determined.	1 month
Secondary	Variation of plasma glucagon like peptide-1 concentration	Measure of plasma glucagon like peptide-1 concentrations (mg/dL)	1 month
Secondary	Variation of plasma gastric inhibitory polypeptide hormone concentration	Measure of plasma gastric inhibitory polypeptide concentrations (mg/dL)	1 month
Secondary	Variation of plasma Glucagon hormone concentration	Measure of plasma Glucagon concentrations (mg/dL)	1 month
Secondary	Variation of plasma Ghrelin hormone concentration	Measure of plasma Ghrelin concentrations (mg/dL)	1 month
Secondary	Variation of plasma Insulin hormone concentration	Measure of plasma Insulin concentrations (mg/dL)	1 month
Secondary	Variation of plasma endocannabinoids and N-acyl-ethanolamines concentration	Measure of plasma endocannabinoids and N-acyl-ethanolamines concentrations (mg/dL)	1 month
Secondary	Variation of serum dipeptidyl-dipeptidase-IV activity	Measure of activity of dipeptidyl-dipeptidase-IV activity (U/L)	1 month
Secondary	Changes in body weight	Measure of body weight in fasting subjects	1 month
Secondary	Changes in body mass index	Calculation of body mass index by the formula weight in kilograms divided by height in meters squared.	1 month
Secondary	Changes in waist circumference	Measure of waist circumference at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest, with the tape parallel to the floor.	1 month
Secondary	Changes in hip circumference	Measure of hip circumference around the widest portion of the buttocks, with the tape parallel to the floor.	1 month
Secondary	Changes in blood pressure	Measure of systolic pressure and diastolic pressure in millimetres of mercury (mmHg) by using a digital sphygmomanometer	1 month
Secondary	Changes in body composition	Body composition is determined by conventional bioelectrical impedance analysis with a single-frequency 50 kilohertz (kHz) bioelectrical impedance analyzer in the postabsorptive state (fasting subjects) and after being in the supine position for 20 min. Body composition data will be calculated from bioelectrical measurements and anthropometric data by using validated predictive equations.	1 month
Secondary	Variation of daily energy intakes	Calculation of total daily energy intakes based on 7 days food records	1 month
Secondary	Variation of hunger sensation scores	Measures of hunger sensation over the day reported by subjects by using hunger Visual Analogue Scales (VAS) 0-10 centimeters. Changes in these scores may reflect potential effects of dietary intervention in modulating hunger.	1 month
Secondary	Variation of fullness sensation scores	Measure of fullness sensation over the day reported by subjects by using fullness Visual Analogue Scales (VAS) 0-10 centimeters. Changes in these scores may reflect potential effects of dietary intervention in modulating fullness.	1 month
Secondary	Variation of satiety sensation scores	Measure of satiety sensation over the day reported by subjects by using satiety Visual Analogue Scales (VAS) 0-10 centimeters. Changes in these scores may reflect potential effects of dietary intervention in modulating satiety.	1 month
Secondary	Variation of wellbeing status	Estimate of wellbeing status by mean of quality of life (QoL) questionnaire, which is based on Short Form-12 Health Survey (SF-12), a self-report form of subjective health. Physical and Mental Health Composite Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.	1 month